MetaCap

Fate Therapeutics (FATE) vs Protara Therapeutics (TARA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Fate Therapeutics (FATE) has outperformed Protara Therapeutics (TARA) over the past year, losing 10.8% versus a loss of 68.6%. Over five years, TARA leads with a -67.8% price change compared with -98.3% for FATE. Protara Therapeutics is the larger company by market cap ($140.4 million vs $111.8 million), about 1.3 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

FATE-10.78%TARA-68.60%
+216%+66%-84%
Nov 21, 20251 yearNov 20, 2026
FATE-98.36%TARA-68.33%
+21%-42%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

FATE versus TARA key metrics
MetricFATETARA
Share price$0.919$2.28
Market cap$111.82M$140.38M
1-day change-9.01%-5.00%
YTD return-6.22%-57.22%
1-year return-10.78%-68.60%
5-year return-98.25%-67.80%
EPS (TTM)$-1.03$-1.39
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$6.65M—
Revenue growth (YoY)-51.24%—
Net income (latest FY)$-136.31M$-57.44M
Operating margin-2222.45%—
Net margin-2051.08%—
52-week high$3.23$7.82
52-week low$0.90$2.09
Distance from 52-week high-71.55%-70.84%
Analyst consensusbuystrong_buy
Avg. price target upside+522.42%+1010.96%
Average volume1.53M1.07M
Shares outstanding121.67M61.57M
Employees16146
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • FATE has outperformed TARA by 57.8 percentage points over the past year.

About Fate Therapeutics

FATE stock →

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 161 employees

About Protara Therapeutics

TARA stock →

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 46 employees

FATE vs TARA FAQ

Which is bigger, Fate Therapeutics or Protara Therapeutics?

Protara Therapeutics (TARA) is larger, with a market capitalization of $140.38M compared with $111.82M for Fate Therapeutics (FATE).

Which stock has performed better over the past year, FATE or TARA?

FATE returned -10.78% over the past 12 months, compared with -68.60% for TARA (price return, excluding dividends). Past performance does not predict future results.

Are Fate Therapeutics and Protara Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons